End-Stage Renal Disease Market

Global End-Stage Renal Disease Market Size, Trends & Analysis - Forecasts to 2026 By Disease Type (Chronic Kidney Disease, End-Stage Renal Disease (ESRD), Kidney Failure) By Treatment (Transplant, Dialysis [Peritoneal Dialysis, Hemodialysis, Wearable Artificial Kidney]), By Region (North America, Europe, Asia Pacific, MEA, and CSA), End-User Landscape, Company Market Share Analysis, and Competitor Analysis

Category Healthcare

Format

This report was recently updated on April 30 2024 with the latest and most recent market numbers

End-Stage Renal Disease Market Insights

The global end-stage renal disease market size is projected to grow from USD 74.01 billion in 2021 to USD 144.09 billion by 2026 at a CAGR value of 12.1%.

The end-stage renal disease (ESRD) market is predicted to be driven by a spike in the number of kidney failure sufferers and the development of technologically improved medical devices and equipment such as minimal dialysis equipment and artificial kidneys. The continuing Covid-19 epidemic has raised the demand for home dialysis throughout the globe. Patients with end-stage renal disease, kidney failure, and kidney disease have increased dramatically in North America and other Asian countries, coupled with a rise in the frequency of diabetes and hypertension. These factors act as the key drivers favouring the end-stage renal disease market's expansion. On the other hand, various irregularities in the functioning of kidney transplant therapies, coupled with the negative impacts on social status and a lack of knowledge have been identified as the challenges of the market.

Upgrades in the technology utilized in the treatment of end-stage renal failure are also assisting in offering better care and satisfaction, which, along with improved outcomes, is boosting consumption and growth in the end-stage renal disease market. Diabetes is the leading cause of severe kidney disease, followed by hypertension, which affects an estimated 1 billion people worldwide. Women are thought to have a higher prevalence of chronic renal disease than males.

It is sometimes referred to as renal failure. Any disorder that causes decreased kidney function results in chronic kidney disease, which can progress over time to end-stage renal disease (ESRD), in which the kidneys can no longer operate on their own. It is also known as renal failure. To stay alive, those with ESRD/CKD must undergo kidney transplantation or dialysis. Hypertension, diabetes, smoking, and aging are all risk factors for end-stage renal disease. Diabetes is the most prevalent cause of ESRD, followed by hypertension (high blood pressure).

Furthermore, the demand for blood tests is predicted to rise as the prevalence of CKD rises in various parts of the world. The global prevalence of end-stage renal disease (ESRD) is substantial and rapidly growing. According to the Global Burden of Disease Study, 697.55 million cases with all-stage CKD were observed in 2018, with a global prevalence of 91%.

global end-stage renal disease market

End-Stage Renal Disease Market: By Disease Type

Based on the disease type in the market end-stage, renal disease is divided into chronic kidney disease, end-stage renal disease (ESRD), kidney failure in this market. One of the key causes of the rising number of kidney failure patients is chronic kidney disease (CKD). Hence, this segment is ought to be growing the fastest. According to the National Kidney Foundation (NKD), CKD affects around 10% of the world population, with millions dying each year. According to the NKD, emerging nations such as China and India have a geriatric population that is suffering. The number of patients who need a kidney transplant or dialysis to keep alive is increasing at a rate of about 7% every year. Women are thought to have a higher prevalence of chronic renal disease than males.

End-Stage Renal Disease Market: By Treatment

Based on the type of treatment the market is segregated into transplant and dialysis. The dialysis sector holds the largest share of the market during the forecast period. Dialysis is more convenient and simpler to organize for an ESRD patient, and the process can be conducted at a dialysis clinic or home. Furthermore, patients are not required to rely on donor organs, which are in short supply as compared to dialysis equipment. Dialysis is the only option for patients in developing, densely populated, or low-income nations who do not qualify for transplant surgery. As a result, the benefits provided by dialysis are projected to promote segment expansion.

asia pacific end-stage renal disease market

End-Stage Renal Disease Market: By Region

As per the geographical analysis, the market can be classified into North America (the US, Canada, and Mexico), Asia Pacific (India, China, Japan, Malaysia, Singapore, and Rest of Asia Pacific), Europe (Germany, United Kingdom, Italy, France, Spain, Netherlands, and Rest of Europe), Middle East & Africa and Central & South America.

APAC is estimated to be the largest market for the end-stage renal disease Industry during the mentioned forecast period. Increasing investments made in the research and development activities to launch advanced medical devices to treat ESRD will drive the market. In 2020, Asia Pacific dominated the ESRD market based on the CAGR value and is analyzed to maintain this trend. This is due to increased healthcare expenditure, enhanced government efforts, rising CKD awareness campaigns, and the presence of newly created state-of-the-art healthcare facilities in the region. High blood pressure and diabetes are two of the most frequent risk factors for renal disease.

Among the world population, the African-Middle Eastern ethnicity is the most prone to CKD. The prevalence of CKD is 18 to 23% of the total population in African-Middle Eastern countries, which is much higher than the world population. Hence, the MEA region will be the second fastest growing segment in the market.

End-Stage Renal Disease Market Share and Competitor Analysis

Nipro Corporation; Fresenius Medical Care AG & Co. KGaA; Baxter International, Inc.; Medtronic Plc; B. Braun Melsungen AG; BD; Abbott Laboratories, Asahi Kasei Medical Co., Ltd.; Cantel Medical; Nikkiso Co., Ltd.; JMS Co. Ltd. are the major players in the end-stage renal disease market.

Please note: This is not an exhaustive list of companies profiled in the report.

These players are working on various marketing strategies, including R&D activities, a growing number of collaborations, awareness programs, technological progress, geographical expansion and the launching of new products, to increase their market share.

In October 2019, Fresenius Medical Care received a device designation from the FDA for its new hemodialysis equipment, which is to prevent blood clotting without the use of drugs.

Chapter 1 Methodology

1.1 Market Scope & Definitions

1.2 Estimates & Forecast Calculation

1.3 Historical Data Overview and Validation

1.4 Data Sources

1.4.1 Secondary

1.4.2 Primary

Chapter 2 Report Outlook

2.1 Global End Stage Renal Disease Market Overview, 2019-2026

2.1.1 Industry Overview

2.1.2 Treatment Overview

2.1.3 Disease Type Overview

2.1.4 Regional Overview

Chapter 3 Global End Stage Renal Disease Market Trends

3.1 Market Segmentation

3.2 Industry Background, 2019-2026

3.3 Market Key Trends

3.3.1 Positive Trends

3.3.1.1 Growing prevalence of diabetes and hypertension

3.3.1.2 Increasing technologically advanced Treatments

3.3.2 Industry challenges

3.3.2.1 Risk of complications

3.4 Prospective Growth Scenario

3.4.1 Treatment Overview

3.4.2 Disease Type Overview

3.5 COVID-19 Influence over Industry Growth

3.6 Porter’s Analysis

3.7 PESTEL Analysis

3.8 Value Chain & Supply Chain Analysis

3.9 Regulatory Framework

3.9.1 North America

3.9.2 Europe

3.9.3 APAC

3.9.4 LATAM

3.9.5 MEA

3.10 Disease Type Overview

3.11 Market Share Analysis, 2020

3.11.1 Company Positioning Overview, 2020

Chapter 4 Global End Stage Renal Disease Market, By Disease Type

4.1 Disease Type Outlook

4.2 Chronic Kidney Disease

4.2.1 Market Size, By Region, 2019-2026 (USD Billion)

4.3 End-Stage Renel Disease

4.3.1 Market Size, By Region, 2019-2026 (USD Billion)

4.4 Kidney Failure

4.4.1 Market Size, By Region, 2019-2026 (USD Billion)

Chapter 5 Global End Stage Renal Disease Market, By Treatment

5.1 Treatment Outlook

5.2 Transplant

5.2.1 Market Size, By Region, 2019-2026 (USD Billion)

5.3 Dialysis

5.3.1 Market Size, By Region, 2019-2026 (USD Billion)

5.3.1.1 Peritoneal Dialysis Market Size, By Region, 2019-2026 (USD Billion)

5.3.1.2 Hemodialysis Market Size, By Region, 2019-2026 (USD Billion)

5.3.1.3 Wearable Artificial Kidney Market Size, By Region, 2019-2026 (USD Billion)

Chapter 6 Global End Stage Renal Disease Market, By Region

6.1 Regional outlook

6.2 North America

6.2.1 Market Size, By Country 2019-2026 (USD Billion)

6.2.2 Market Size, By Disease Type, 2019-2026 (USD Billion)

6.2.3 Market Size, By Treatment, 2019-2026 (USD Billion)

6.2.4 U.S.

6.2.4.1 Market Size, By Disease Type, 2019-2026 (USD Billion)

6.2.4.2 Market Size, By Treatment, 2019-2026 (USD Billion)

6.2.5 Canada

6.2.5.1 Market Size, By Disease Type, 2019-2026 (USD Billion)

6.2.5.2 Market Size, By Treatment, 2019-2026 (USD Billion)

6.3 Europe

6.3.1 Market Size, By Country 2019-2026 (USD Billion)

6.3.2 Market Size, By Disease Type, 2019-2026 (USD Billion)

6.3.3 Market Size, By Treatment, 2019-2026 (USD Billion)

6.3.4 Germany

6.3.4.1 Market Size, By Disease Type, 2019-2026 (USD Billion)

6.3.4.2 Market Size, By Treatment, 2019-2026 (USD Billion)

6.3.5 UK

6.3.5.1 Market Size, By Disease Type, 2019-2026 (USD Billion)

6.3.5.2 Market Size, By Treatment, 2019-2026 (USD Billion)

6.3.6 France

6.3.6.1 Market Size, By Disease Type, 2019-2026 (USD Billion)

6.3.6.2 Market Size, By Treatment, 2019-2026 (USD Billion)

6.3.7 Italy

6.3.7.1 Market Size, By Disease Type, 2019-2026 (USD Billion)

6.3.7.2 Market Size, By Treatment, 2019-2026 (USD Billion)

6.3.8 Spain

6.3.8.1 Market Size, By Disease Type, 2019-2026 (USD Billion)

6.3.8.2 Market Size, By Treatment, 2019-2026 (USD Billion)

6.3.9 Russia

6.3.9.1 Market Size, By Disease Type, 2019-2026 (USD Billion)

6.3.9.2 Market Size, By Treatment, 2019-2026 (USD Billion)

6.4 Asia Pacific

6.4.1 Market Size, By Country 2019-2026 (USD Billion)

6.4.2 Market Size, By Disease Type, 2019-2026 (USD Billion)

6.4.3 Market Size, By Treatment, 2019-2026 (USD Billion)

6.4.4 China

6.4.4.1 Market Size, By Disease Type, 2019-2026 (USD Billion)

6.4.4.2 Market Size, By Treatment, 2019-2026 (USD Billion)

6.4.5 India

6.4.5.1 Market Size, By Disease Type, 2019-2026 (USD Billion)

6.4.5.2 Market Size, By Treatment, 2019-2026 (USD Billion)

6.4.6 Japan

6.4.6.1 Market Size, By Disease Type, 2019-2026 (USD Billion)

6.4.6.2 Market Size, By Treatment, 2019-2026 (USD Billion)

6.4.7 Australia

6.4.7.1 Market Size, By Disease Type, 2019-2026 (USD Billion)

6.4.7.2 Market size, By Treatment, 2019-2026 (USD Billion)

6.4.8 South Korea

6.4.8.1 Market Size, By Disease Type, 2019-2026 (USD Billion)

6.4.8.2 Market Size, By Treatment, 2019-2026 (USD Billion)

6.5 Latin America

6.5.1 Market Size, By Country 2019-2026 (USD Billion)

6.5.2 Market Size, By Disease Type, 2019-2026 (USD Billion)

6.5.3 Market Size, By Treatment, 2019-2026 (USD Billion)

6.5.4 Brazil

6.5.4.1 Market Size, By Disease Type, 2019-2026 (USD Billion)

6.5.4.2 Market Size, By Treatment, 2019-2026 (USD Billion)

6.5.5 Mexico

6.5.5.1 Market Size, By Disease Type, 2019-2026 (USD Billion)

6.5.5.2 Market Size, By Treatment, 2019-2026 (USD Billion)

6.5.6 Argentina

6.5.6.1 Market Size, By Disease Type, 2019-2026 (USD Billion)

6.5.6.2 Market Size, By Treatment, 2019-2026 (USD Billion)

6.6 MEA

6.6.1 Market Size, By Country 2019-2026 (USD Billion)

6.6.2 Market Size, By Disease Type, 2019-2026 (USD Billion)

6.6.3 Market Size, By Treatment, 2019-2026 (USD Billion)

6.6.4 Saudi Arabia

6.6.4.1 Market Size, By Disease Type, 2019-2026 (USD Billion)

6.6.4.2 Market Size, By Treatment, 2019-2026 (USD Billion)

6.6.5 UAE

6.6.5.1 Market Size, By Disease Type, 2019-2026 (USD Billion)

6.6.5.2 Market Size, By Treatment, 2019-2026 (USD Billion)

6.6.6 South Africa

6.6.6.1 Market Size, By Disease Type, 2019-2026 (USD Billion)

6.6.6.2 Market Size, By Treatment, 2019-2026 (USD Billion)

Chapter 7 Company Landscape

7.1 Competitive Analysis, 2020

7.2 Nipro Corporation

7.2.1 Company Overview

7.2.2 Financial Analysis

7.2.3 Strategic Positioning

7.2.4 Info-Graphic Analysis

7.3 Baxter International, Inc.

7.3.1 Company Overview

7.3.2 Financial Analysis

7.3.3 Strategic Positioning

7.3.4 Info-Graphic Analysis

7.4 Fresenius Medical Care AG & Co. KGaA

7.4.1 Company Overview

7.4.2 Financial Analysis

7.4.3 Strategic Positioning

7.4.4 Info-Graphic Analysis

7.5 Medtronic Plc

7.5.1 Company Overview

7.5.2 Financial Analysis

7.5.3 Strategic Positioning

7.5.4 Info-Graphic Analysis

7.6 B. Braun Melsungen AG

7.6.1 Company Overview

7.6.2 Financial Analysis

7.6.3 Strategic Positioning

7.6.4 Info-Graphic Analysis

7.7 Asahi Kasei Medical Co., Ltd.

7.7.1 Company Overview

7.7.2 Financial Analysis

7.7.3 Strategic Positioning

7.7.4 Info-Graphic Analysis

7.8 Cantel Medical

7.8.1 Company Overview

7.8.2 Financial Analysis

7.8.3 Strategic Positioning

7.8.4 Info-Graphic Analysis

7.9 Abbott Laboratories.

7.9.1 Company Overview

7.9.2 Financial Analysis

7.9.3 Strategic Positioning

7.9.4 Info-Graphic Analysis

7.10 JMS Co. Ltd.

7.10.1 Company Overview

7.10.2 Financial Analysis

7.10.3 Strategic Positioning

7.10.4 Info-Graphic Analysis

7.11 Becton, Dickinson and Company

7.11.1 Company Overview

7.11.2 Financial Analysis

7.11.3 Strategic Positioning

7.11.4 Info-Graphic Analysis

7.12 Other Companies

7.12.1 Company Overview

7.12.2 Financial Analysis

7.12.3 Strategic Positioning

7.12.4 Info-Graphic Analysis

The Global End-Stage Renal Disease Market has been studied from the year 2019 till 2026. However, the CAGR provided in the report is from the year 2021 to 2026. The research methodology involved three stages: Desk research, Primary research, and Analysis & Output from the entire research process.

The desk research involved a robust background study which meant referring to paid and unpaid databases to understand the market dynamics; mapping contracts from press releases; identifying the key players in the market, studying their product portfolio, competition level, annual reports/SEC filings & investor presentations; and learning the demand and supply-side analysis for the End-Stage Renal Disease Market.

The primary research activity included telephonic conversations with more than 50 tier 1 industry consultants, distributors, and end-use product manufacturers.

Finally, based on the above thorough research process, an in-depth analysis was carried out considering the following aspects: market attractiveness, current & future market trends, market share analysis, SWOT analysis of the company and customer analytics.

We value your investment and offer free customization with every report to fulfil your exact research needs.

This website is secure and your personal details are safe. Privacy

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

What is the projected market size of the global end-stage renal disease coating market?

The global end-stage renal disease coating market size is projected to grow from USD 74.01 billion in 2021 to USD 144.09 billion by 2026, at a CAGR of 12.1% during the forecast period.

Who are the major vendors in the end-stage renal disease coating market?

Key and innovative vendors in the end-stage renal disease coating market include Nipro Corporation; Fresenius Medical Care AG & Co. KGaA; Baxter International, Inc.; Medtronic Plc; B. Braun Melsungen AG; BD; Abbott Laboratories, Asahi Kasei Medical Co., Ltd.; Cantel Medical; Nikkiso Co., Ltd.; JMS Co. Ltd.

Which region has the highest market share in the end-stage renal disease coating market?

The Asia Pacific region is estimated to hold the highest market share in the end-stage renal disease coating market.

What is the Covid-19 impact on future end-stage renal disease coating manufacturers?

Globally, Covid-19 impact on the future end-stage renal disease coating market will be quite significant for the manufacturers. The Asia Pacific region would be leading because of the increasing investments made in the research and development activities to launch advanced medical devices to treat ESRD. Subsequently, MEA is the worlds second-largest market because of the uptick in the prevalence of CKD.

What are the major drivers in the end-stage renal disease coating market?

The major driving factors for the end-stage renal disease coating market include the rising number of kidney and renal failure sufferers; soaring development of technologically improved medical devices and equipment; increasing geriatric demographics; launch of low-maintenance dialysis devices and artificial kidney; growing lifestyle stress.